Over at ADVFN message board a poster called (culver) wrote this on the message board. ("Reply from liquidators' office to my request for a 6m update:") "Unfortunately we cannot confirm when the final distribution will be declared, the liquidation will last at least another 12 months to enable the Joint Liquidators to realise the companys assets in full. There will likely be another distribution at an estimated 4 to 7 pence per share which is expected to be towards the end of the liquidation."
Contacted administrators who were struggling with anyone other than small individual investors. Nominee investors through brokers such as Hlafiax Share Dealing did not seem to be identified. A few hours later I was conatcted to say Halifax Share Dealing ( LLoyds) had now been recognised and payment to those shareholders would be this week coming at a level of 7.41p per share.
I have some stars and from the information I ve read from the people who are administrators the payout is around 15 pence per share. Im disappointed as i read Stanmore was bought buy another company for 30 million pounds or more. MDY healthcare must have had lots of liabilities likes bonds and loans to pay before they arrived at the 15 pence per shares.
I am hoping that we can gain further information today and if so, I will post it on here.
Overall and under the stewardship of Charles Spicer the majority of MDY investments did well. I am current very heavy in Allergy Therapeutics which was one of Spicer's astute buys.
A mixture, of bad luck, poor timing and world economics let us all down
But as the song says, "that was yesterday and yesterdays is gone"!
MediaZest, the creative digital out-of-home advertising company, is pleased to
announce two significant new contract wins.
The Group is providing programming, development and installation services for a
large multi-national Company and their partners developing a new retail
concept. The initial project is expected to generate revenues of approximately
£400,000 with future potential to roll out across multiple UK locations and
In addition several new contracts have been won in the Education sector, with
value over £220,000 the largest of which will generate revenues totalling £
All of these projects are scheduled to be delivered in the quarter ended 31
Despite only soft launching in October 2014, the Company has already made its
first sale of, and deployed, the product to a global retailer for an initial
site. It expects to announce further similar deals in the next quarter.
"The Company is very pleased at the support it has received from both new and
existing shareholders which is testament to the progress that MediaZest has
made. The recent launch of our own Retail Analytics product has been very well
received, with the first client location already deployed. The funds raised
from the Placing will enable us to further develop this product, and pursue
other opportunities to roll it out with major retailers and also enable us to
build upon recent new business gains. The Retail Analytics product and our
strategy of focussing on high profile clients is already enabling us to
supplement existing recurring revenues."
I have invested here because I can see that 2015 could be a great year for MDZ, once the placing has gone through in early January I expect MDZ will release positive news regarding more new contracts with major retailers, and the SP will rocket, there Retail Analytics product is fantastic, which makes this a really unique company to invest in.
Contacted mdy to see if any payment would come in the future. I go their snail from the website.
So far they have said they will get back to me but that was 2 months ago.
I have sent repeated emails but now they are not responding.
speaking to myself ..
'MDY Healthcare has invested £3 million in the transaction and will have
approximately 20% of the issued share capital on a fully-diluted basis. Charles
Spicer, CEO of MDY Healthcare and Tim Haines a Partner at Abingworth, who will
be investing £8.5m, have been appointed to the board of SIW.' http://www.mdyhealthcare.com/ir/mdy/ir.jsp?page=news-item&item=60917668718210
'The directors of MDY Healthcare are pleased to announce payment of a special dividend of 6 pence per share, following the receipt of escrow funds by MDY Healthcare relating to the disposal of its investment in Medivance Inc.
The dividend is payable on 21 June 2013, to shareholders of record on 7 June 2013.
MDY Healthcare currently holds an investment in one private company, Stanmore Implants, an innovative orthopaedic business focused on saving and restoring the function of limbs and joints. MDY Healthcare intends to manage its investment in Stanmore going forward with a view to realising this investment at the appropriate time in order to return value to MDY Healthcares shareholders.
MDY Healthcare also announces at this time that it is cancelling its trading facility on the Asset Match trading platform. Therefore, MDY Healthcares shares will no longer be capable of being traded on Asset Match with effect from 16 September 2013.'
London, England March , 2013 - Stanmore Implants Worldwide, Ltd. (Stanmore), a pioneer in advanced orthopedic implant technologies, announces that Michael R. Mainelli, Jr. has been appointed President & Chief Executive Office and a member of the Board of Directors of the Company. He succeeds Brian Steer, a founding member of Stanmore, who will remain the company's Chairman.
Mike Mainelli is a proven global medical device executive with an outstanding track record for building high performing teams, commercializing new technologies and delivering operational results. He has over 20 years experience in the medical device and health care industry. Most recently he served as President and CEO of Active Implants Corporation, a company developing a novel meniscal implant. Prior to that, he served as President of Stryker Spine and President of Stryker Japan. He began his career at General Electric Company where he worked in a number of business units rising to an executive role at GE Medical Systems, now called GE Healthcare.
The Board is very grateful for Brian Steer's founding work and significant contribution to the development of the Company and delighted that he will continue with us as Chairman of the Board," said Timothy Haines, a member of the Board and Partner with Abingworth, a principal investor in Stanmore. "Over the last five years Brian has led the formation of the Company, included two rounds of financing, acquired key technologies, and recruited a first class management team. We thank Brian for the vision and leadership and look forward to his continued involvement.
Brian Steer said, "I welcome Mike to the team. He has the requisite skills to take the company to the next level and now is the time to transition to new leadership. I'm extremely proud of all that we have accomplished over the last five years and pleased to remain part of Stanmore and to be working with Mike in my capacity as Chairman."
Michael Mainelli commented that "I'm proud to be joining Stanmore at this exciting and important stage of development. Stanmore is uniquely positioned in the orthopaedic market with multiple, differentiated platform technologies designed to serve important, yet underserved market segments. We look forward to commercializing these technologies in the US and on a global basis."
He holds an MBA from the University of Chicago, an MSE from the University of Pennsylvania and a BSME from Northeastern University. He is a member of the Board of Directors of Orthofix International and Autocam Corporation/Autocam Medical and also served on the board of Active Implants from 2008 through 2011.
FTI Consulting - Ben Atwell, Stephanie Cuthbert, Mo Noonan
Tel: +44 (0) 20 7831 3113
Notes to Editors
Stanmore Implants is a commercial-stage orthopaedic implant company focused on providing differentiated technologies designed to provide solutions for several important, yet underserved market segments.
Stanmore's implant design service alongside its portfolio of orthopaedic implants draws on over 60 years' experience in providing some of the world's most successful implants in Extreme Orthopedics.
Stanmore recently announced FDA approval for the Sculptor RGA robotic technology. Stanmore's goal is to provide surgeons with a more clinical and cost-effective solution compared with current treatment options. Initially, the Sculptor RGA is approved for use in unicompartmental knee replacement, a global market estimated to be 150,000 procedures per year with a market value of approximately $450 MM.
Stanmore is backed by leading investors including Abingworth, Imperial Innovations and Ivy Capital and intends to seek like-minded co-investors in 2013 to further support the commercialisation and growth opportun
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.